Investors News Releases News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Corporate Factsheet Annual Reports News Releases Year None20222021202020192018201720162015201420132012201120102009200820072006 Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Aug 03 2022 Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors May 11 2022 Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update May 04 2022 Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas Apr 12 2022 Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia Mar 28 2022 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Mar 22 2022 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results Pagination Current page 1 Page 2 Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None20222021202020192018201720162015201420132012201120102009200820072006 Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Aug 03 2022 Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors May 11 2022 Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update May 04 2022 Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas Apr 12 2022 Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia Mar 28 2022 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Mar 22 2022 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results Pagination Current page 1 Page 2 Next page next › Last page last »
Aug 10 2022 Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Jun 30 2022 Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline
Jun 22 2022 Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors
May 11 2022 Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 19 2022 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas
Apr 12 2022 Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia
